All of the following toxicities are known with linezolid, EXCEPT:

The principal toxicity of linezolid is hematologic--reversible and generally mild. Thrombocytopenia is the most common manifestation (seen in approximately 3% of treatment courses), paicularly when the drug is administered for longer than 2 weeks. Anemia and neutropenia may also occur, most commonly in patients with a predisposition to or underlying bone marrow suppression. Cases of optic and peripheral neuropathy and lactic acidosis have been repoed with prolonged courses of linezolid. These side effects are thought to be related to linezolid-induced inhibition of mitochondrial protein synthesis. Ref: Katzung 11th edition Chapter 44.